Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) : a consensus conference proposal for a standardized approach
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1196413
Author(s)
Halter, J; Schüpbach, W M M; Casali, C; Elhasid, R; Fay, K; Hammans, S; Illa, I; Kappeler, L; Krähenbühl, S; Lehmann, T; Mandel, H; Marti, R; Mattle, H; Orchard, K; Savage, D; Sue, C M; Valcarcel, D; Gratwohl, A; Hirano, M
Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) : a consensus conference proposal for a standardized approach
Allogeneic hematopoietic SCT (HSCT) has been proposed as a treatment for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). HSCT has been performed in nine patients using different protocols with varying success. Based on this preliminary experience, participants of the first consensus conference propose a common approach to allogeneic HSCT in MNGIE. Standardization of the transplant protocol and the clinical and biochemical assessments will allow evaluation of the safety and efficacy of HSCT as well as optimization of therapy for patients with MNGIE.
